| gap-pubmed-20260410- | How does peripheral tumor-induced gut dysbiosis contribute to brain inflammation | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms mediate peripheral tumor-induced disruption of intestinal barrie | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What makes mitochondrial biomarkers reliable for detecting pre-symptomatic neuro | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can mitochondrial-targeted therapies overcome the translation barriers from | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the feedforward cycles between ROS overproduction and neur | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the long-term safety and efficacy profiles of circSCMH1@LNP1 treatment | open | 0.82 | 0.00 | 2026-04-10 | 0 | | translational-neuroscience |
| gap-pubmed-20260410- | How does intranasal delivery achieve preferential targeting to peri-infarct regi | open | 0.75 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-pubmed-20260410- | What molecular mechanisms underlie circSCMH1's diverse therapeutic effects on sy | open | 0.80 | 0.00 | 2026-04-10 | 0 | | stroke-recovery |
| gap-pubmed-20260410- | What kinase/phosphatase pathways regulate NLRP3 Serine 658 phosphorylation in ne | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does Psoralen specifically prevent phosphorylation at Serine 658 through NAC | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the variable penetrance of mutational signatures across differen | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do single-strand DNA lesions serve as precursors to disease-associated sInde | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link TOP1-mediated mutagenesis to neuronal death in neurodegener | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do NPD types A and B have different phenotypes despite identical genetic def | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms determine why NPD type B shows preferential lung involvement com | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the mechanistic relationship between clathrin heavy chain reduction and | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does α-synuclein specifically accumulate in ER and mitochondria rather than | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does DNAJC6 paucity specifically reduce lysosome number and what determines | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does impaired microglial phagocytosis specifically increase spontaneous seiz | open | 0.76 | 0.00 | 2026-04-10 | 0 | | epilepsy |
| gap-pubmed-20260410- | What molecular mechanisms link TREM2-mediated phagocytic clearance to seizure su | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the optimal therapeutic PGRN levels needed to restore function w | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does autophagy and lysosome dysfunction mechanistically connect PGRN deficie | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the molecular mechanisms by which PGRN insufficiency leads to TDP43 acc | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the contribution of epigenetic mechanisms versus other pathways in alumi | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do aluminum-induced changes in DNMTs and TETs specifically alter neuronal ge | open | 0.79 | 0.00 | 2026-04-10 | 0 | | epigenetics |
| gap-pubmed-20260410- | What are the causal mechanisms linking aluminum-induced epigenetic changes to AD | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the observed proteomic changes translate to functional cellular and behav | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link chronic LRRK2 inhibition to tissue-specific pathway alterat | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does LRRK2 autophosphorylation show different kinetics than Rab substrate ph | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does NUB1 modulation of GSK3β affect other GSK3β-dependent pathways beyond t | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of NUB1's effects on GSK3β versus other kinases | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does NUB1 suppress tau phosphorylation and aggregation independently of GSK3 | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does ePVS burden show regional variation with frontal lobe being most affect | open | 0.73 | 0.00 | 2026-04-10 | 0 | | traumatic-brain-injury |
| gap-pubmed-20260410- | What mechanisms link poor sleep quality to accelerated ePVS burden increase in T | open | 0.79 | 0.00 | 2026-04-10 | 0 | | traumatic-brain-injury |
| gap-pubmed-20260410- | What signals trigger VCPIP1's nuclear-to-cytoplasmic translocation upon TLR4 act | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanism enables VCPIP1 to block K48 ubiquitination of IRAK1/2 w | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines tissue-specific palmitoylation patterns of SRPK1 in neuronal vs | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does SRPK1-p53 signaling suppress ferroptosis when p53 typically promotes ce | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do enteric glia specifically contribute to α-synuclein propagation from gut | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which gut microbiota alterations t | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does gastrointestinal inflammation causally contribute to alpha-synuclein pa | open | 0.86 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which gut microbiota signals trave | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do clinical features mechanistically relate to true vs. false positive MOG-I | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What biological mechanisms cause 33% false positive rate in MOG-IgG testing desp | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the key challenges limiting EVs as effective drug delivery vehicles for | open | 0.82 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-pubmed-20260410- | What specific mechanisms govern how brain-derived EVs mediate disease progressio | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why is HS-Aging frequently misdiagnosed as Alzheimer's disease despite distinct | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do hippocampal sclerosis mechanisms specifically relate to emotional process | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms underlying drug-resistant temporal lo | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the timing and dosing regimen of exosome therapy affect neuroprotective | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |